News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tocris Bioscience Signs Exclusive Deal to Supply Gefitinib for Cancer Research


9/9/2008 2:22:06 PM

Tocris Bioscience (Bristol, UK) announced today the signing of an exclusive deal with AstraZeneca to supply Gefitinib (also known as Iressaâ„¢ and ZD1839) to preclinical researchers working on the mechanisms underlying cancer development. For the first time, scientists will be able to buy authentic, fully licensed, non-formulated Gefitinib as an off-the shelf product for use in biological research.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES